DXCM Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 4383 min ago

@ $137.94

Ausgestellt: 25 Apr 2024 @ 21:42

Rendite: -9.86%

Vorheriges Signal: Apr 25 - 18:41

Vorheriges Signal: Verkaufen

Rendite: 0.81 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally...

Stats
Tagesvolumen	8.55M
Durchschnittsvolumen	3.17M
Marktkapitalisierung	49.24B
EPS	$0 ( 2024-04-25 )
Nächstes Ertragsdatum	( $0.390 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	95.65
ATR14	$13.59 (10.93%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Dolan Matthew Vincent	Sell	1 990	Common Stock
2024-04-08	Sayer Kevin R	Sell	27 272	Common Stock
2024-04-08	Sayer Kevin R	Sell	22 361	Common Stock
2024-03-28	Brown Michael Jon	Sell	2 524	Common Stock
2024-03-28	Brown Michael Jon	Sell	100	Common Stock

INSIDER POWER
-3.99
Last 99 transactions
Buy: 330 077 \| Sell: 354 468

Volumen Korrelation

Lang: -0.86 (strong negative)

Kurz: -0.83 (strong negative)

Signal:(37) Neutral

DexCom Inc Korrelation

10 Am meisten positiv korreliert
SVBI	0.821
BOSC	0.807

10 Am meisten negativ korreliert
QTEK	-0.802

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

DexCom Inc Korrelation - Währung/Rohstoff

0.34
( neutral )

0.54
( weak )

0.00
( neutral )

0.62
( weak )

-0.34
( neutral )

-0.47
( neutral )

DexCom Inc Finanzdaten

Annual	2023
Umsatz:	$3.62B
Bruttogewinn:	$2.29B (63.19 %)
EPS:	$1.400

FY	2023
Umsatz:	$3.62B
Bruttogewinn:	$2.29B (63.19 %)
EPS:	$1.400

FY	2022
Umsatz:	$2.91B
Bruttogewinn:	$1.88B (64.72 %)
EPS:	$0.880

FY	2021
Umsatz:	$2.45B
Bruttogewinn:	$1.68B (68.63 %)
EPS:	$0.400

Financial Reports:

No articles found.

DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.